Sign in Subscribe

kras

A collection of 71 issues

Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC A matching-adjusted indirect comparison evaluated sotorasib plus panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice.

KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic

CRC Research Update — August 13, 2026

Today's colorectal cancer research highlights

CRC Research Update — August 10, 2026

Today's colorectal cancer research highlights

KRAS Mutation Sites Associated with Clinical Characteristics in 550 Patients

Skip to content The CRC Digest KRAS Mutation Sites Associated with Clinical Characteristics in 550 Patients A retrospective study investigated the distribution of specific KRAS mutation sites and their associations with clinicopathological parameters and survival outcomes. (Zhong Nan Da Xue Xue Bao Yi Xue Ban) This content is informational only

CRC Research Update — August 07, 2026

Today's colorectal cancer research highlights

CRC Research Update — August 06, 2026

Today's colorectal cancer research highlights

KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer A meta-analysis investigated whether different KRAS mutation subtypes affect pathological complete response rates after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. The study examined KRAS mutations within and outside exon 2.

CRC Research Update — August 01, 2026

Today's colorectal cancer research highlights

CRC Research Update — July 30, 2026

Today's colorectal cancer research highlights